The National Insitute of Health is finally launching All of Us, a huge research study with the aim of making precision medicine available to people of all backgrounds. But will people give up their data?
Deep learning computers in a diagnostic imaging lab routinely defeat their human counterparts in diagnosing heart failure, detecting various cancers and predicting their strength.
Antibiotics in the environment contribute to drug resistance, but researchers have figured out how some soil bacteria turn the drugs into food.
At a discussion of epidemics, Bill Gates revealed that he believes the next deadly disease that will cause a global pandemic is coming, and we should prepare for it like war.
Thermo Fisher Scientific has signed agreements with Takeda Pharmaceuticals and Daiichi Sanyo that will enable the Japanese firms to leverage Thermo Fisher’s FDA approved Oncomine Dx Target Test for their clinical trials and drug development programs.
The Scripps Translational Science Institute has received over $34 million in renewed funding from the National Institutes of Health’s National Center for Advancing Translational Sciences to advance medical research and clinical care through genomic and digital technologies.
Gilead Sciences will partner with Google Parent Alphabet’s Verily Life Sciences over the next three years, applying Verily’s Immunoscape platform to better understand the immunological basis of three common diseases.
Researchers have identified a protein critical for the aggressiveness of T-cell leukaemia, a subtype of leukaemia that afflicts children and adults.
A new method for diagnosing breast cancer involves a pill, which could do a better job distinguishing between benign and aggressive tumours.
The US Court of Appeals has heard the oral arguments for the next round of the patent battle between the UC Berkeley and the Broad Institute of MIT and Harvard.
CRISPR pioneer, Feng Zhang, and his mentor Eric Lander of the Broad Institute share their excitement about the potential of gene editing tool, CRISPR, but stresses that more work needs to be done.
Armed with new insights into the interactions between cancer and the immune system, research teams are developing novel treatments to harness the full potential of the body’s natural defenses.
When you send off a cheek swab to one of the private genome companies, you may sacrifice not just your own privacy but that of your family and your ancestors.
If there is one thing all cancers have in common, it is, they have nothing in common.
Researchers at the Broad Institute of MIT and Harvard have reported that their platform, SHERLOCK, now can be used to detect viruses directly in clinical samples such as blood or saliva.